230 related articles for article (PubMed ID: 30793281)
21. SPAG9 May Be a Potential Prognostic Marker of Endometrial Hyperplasia and Grade 1 Endometrioid Adenocarcinoma Treated with Progestin.
Li C; Bai Y; Yan L; Zhang L; Zhang H; Li M; Zhao M; Gao Y; Zhao X
Gynecol Obstet Invest; 2016; 81(3):267-74. PubMed ID: 26334303
[TBL] [Abstract][Full Text] [Related]
22. Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response.
Tierney KE; Ji L; Dralla SS; Yoo E; Yessaian A; Pham HQ; Roman L; Sposto R; Mhawech-Fauceglia P; Lin YG
Gynecol Oncol; 2016 Dec; 143(3):650-654. PubMed ID: 27771165
[TBL] [Abstract][Full Text] [Related]
23. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women.
Baker WD; Pierce SR; Mills AM; Gehrig PA; Duska LR
Gynecol Oncol; 2017 Jul; 146(1):34-38. PubMed ID: 28427775
[TBL] [Abstract][Full Text] [Related]
24. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
Gunderson CC; Fader AN; Carson KA; Bristow RE
Gynecol Oncol; 2012 May; 125(2):477-82. PubMed ID: 22245711
[TBL] [Abstract][Full Text] [Related]
25. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism.
Hu M; Sun D; Yu J; Fu Y; Qin Z; Huang B; Zhang Q; Chen X; Wei Y; Zhu H; Wang Y; Feng Y; Zheng W; Liao H; Li J; Wu S; Zhang Z
Lab Invest; 2022 Dec; 102(12):1335-1345. PubMed ID: 36038734
[TBL] [Abstract][Full Text] [Related]
26. Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction.
Ørbo A; Kaino T; Arnes M; Larsen K; Pettersen I; Moe B
Acta Obstet Gynecol Scand; 2009; 88(11):1234-42. PubMed ID: 19900140
[TBL] [Abstract][Full Text] [Related]
27. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
[TBL] [Abstract][Full Text] [Related]
28. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study.
Sletten ET; Arnes M; Lyså LM; Larsen M; Ørbo A
BJOG; 2019 Jun; 126(7):936-943. PubMed ID: 30548528
[TBL] [Abstract][Full Text] [Related]
29. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma.
Hubbs JL; Saig RM; Abaid LN; Bae-Jump VL; Gehrig PA
Obstet Gynecol; 2013 Jun; 121(6):1172-1180. PubMed ID: 23812449
[TBL] [Abstract][Full Text] [Related]
30. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
Amezcua CA; Zheng W; Muderspach LI; Felix JC
Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
[TBL] [Abstract][Full Text] [Related]
32. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review.
Allison KH; Tenpenny E; Reed SD; Swisher EM; Garica RL
Appl Immunohistochem Mol Morphol; 2008 Jul; 16(4):329-43. PubMed ID: 18528284
[TBL] [Abstract][Full Text] [Related]
34. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
Gallos ID; Devey J; Ganesan R; Gupta JK
Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
[TBL] [Abstract][Full Text] [Related]
35. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Ørbo A; Arnes M; Lyså LM; Straume B
Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
[TBL] [Abstract][Full Text] [Related]
36. PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: A systematic review and meta-analysis of diagnostic accuracy.
Raffone A; Travaglino A; Saccone G; Mascolo M; Insabato L; Mollo A; De Placido G; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):287-299. PubMed ID: 30511741
[TBL] [Abstract][Full Text] [Related]
37. Utility of a PAX2, PTEN, and β-catenin Panel in the Diagnosis of Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia in Endometrial Polyps.
Lucas E; Niu S; Aguilar M; Molberg K; Carrick K; Rivera-Colon G; Gwin K; Wang Y; Zheng W; Castrillon DH; Chen H
Am J Surg Pathol; 2023 Sep; 47(9):1019-1026. PubMed ID: 37314146
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
Baker J; Obermair A; Gebski V; Janda M
Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
[TBL] [Abstract][Full Text] [Related]
39. PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia.
Strickland AL; Rivera G; Lucas E; John G; Cuevas I; Castrillon DH
Int J Gynecol Pathol; 2019 Nov; 38(6):503-513. PubMed ID: 30256235
[TBL] [Abstract][Full Text] [Related]
40. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]